Notable Labs Notable Labs
  • ABOUT
    • ABOUT US
    • OUR MISSION
    • LEADERSHIP
    • BOARD OF DIRECTORS
  • PLATFORM & PIPELINE
    • PREDICTIVE PRECISION MEDICINE PLATFORM
    • VOLASERTIB & FOSCICLOPIROX
  • NEWS
    • All News
    • Investor Events and Presentations
    • Press Releases
    • Scientific Presentations & Publications
    • Content Search
  • Investors
    • Investor Overview
    • SEC Filings
    • Financials
    • Governance
    • IR Contacts
    • Partnership
    • Stock Information
  • Careers
  1. You are here:  
  2. Publications
  3. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Details
Category: Publications
12.Mar

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Approximately 50% of acute myeloid leukemia (AML) patients do not respond to induction therapy (primary induction failure [PIF]) or relapse after <6 months (early relapse [ER]).

External Link:

https://ashpublications.org/blood/article/137/6/751/463757/Flotetuzumab-as-salvage-immunotherapy-for

 

To learn more, share ideas, or join our mission.
Contact us today!

CONNECT WITH US

  • PRIVACY POLICY
  • TERM OF USE
  • COOKIE STATEMENT
  • INVESTOR OVERVIEW
  • CAREERS
  • CONTACT US

Copyright © 2023 Notable

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.

Accept Decline
Cookie Statement